Sign in
CompletedPhase 3

Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Key facts

Who runs it
Changchun GeneScience Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
313 people enrolled
Started
11 Jan 2023
Ended
3 Apr 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • genakumab
  • placebo for Diprospan
  • placebo for genakumab
  • Diprospan
Record updated
18 December 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Male or female, 18 years ≤ age ≤75 years
  • BMI≤40kg/m2
  • Meeting ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout
  • Start of acute gout flare within 4 days prior to enrolled
  • History of ≥ 2 gout flares within the 12 months prior to study start
  • Evidence of contraindication (absolute or relative), or intolerance, or lack of efficacy for either NSAIDs and/or colchicines
  • Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)

Who cannot take part

  • -

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).

The 2 groups in the trial

  • GenakumabTreatment being tested

    Genakumab 200mg s.c

    Treatment: genakumab and placebo for Diprospan

  • DiprospanExisting treatment, for comparison

    Diprospan 7mg im

    Treatment: placebo for genakumab and Diprospan

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety & Efficacy of Genakumab in Patients With Frequent Flares
Publications
Record updated
18 December 2024